vs

Side-by-side financial comparison of Columbia Financial, Inc. (CLBK) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.

Columbia Financial, Inc. is the larger business by last-quarter revenue ($68.8M vs $38.3M, roughly 1.8× ImmunityBio, Inc.). Columbia Financial, Inc. runs the higher net margin — 22.8% vs -161.8%, a 184.6% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 29.7%). Columbia Financial, Inc. produced more free cash flow last quarter ($58.6M vs $-71.3M).

Ameriprise Financial, Inc. is an American diversified financial services company and bank holding company based in Minneapolis, Minnesota. It provides financial planning products and services, including wealth management, asset management, insurance, annuities, and estate planning.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

CLBK vs IBRX — Head-to-Head

Bigger by revenue
CLBK
CLBK
1.8× larger
CLBK
$68.8M
$38.3M
IBRX
Growing faster (revenue YoY)
IBRX
IBRX
+377.2% gap
IBRX
407.0%
29.7%
CLBK
Higher net margin
CLBK
CLBK
184.6% more per $
CLBK
22.8%
-161.8%
IBRX
More free cash flow
CLBK
CLBK
$129.8M more FCF
CLBK
$58.6M
$-71.3M
IBRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLBK
CLBK
IBRX
IBRX
Revenue
$68.8M
$38.3M
Net Profit
$15.7M
$-61.9M
Gross Margin
99.0%
Operating Margin
28.6%
-169.0%
Net Margin
22.8%
-161.8%
Revenue YoY
29.7%
407.0%
Net Profit YoY
173.9%
-4.7%
EPS (diluted)
$0.15
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLBK
CLBK
IBRX
IBRX
Q4 25
$68.8M
$38.3M
Q3 25
$67.3M
$32.1M
Q2 25
$63.9M
$26.4M
Q1 25
$58.8M
$16.5M
Q4 24
$46.4M
$7.6M
Q3 24
$54.3M
$6.1M
Q2 24
$53.3M
Q1 24
$49.7M
Net Profit
CLBK
CLBK
IBRX
IBRX
Q4 25
$15.7M
$-61.9M
Q3 25
$14.9M
$-67.3M
Q2 25
$12.3M
$-92.6M
Q1 25
$8.9M
$-129.6M
Q4 24
$-21.2M
$-59.2M
Q3 24
$6.2M
$-85.7M
Q2 24
$4.5M
Q1 24
$-1.2M
Gross Margin
CLBK
CLBK
IBRX
IBRX
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
CLBK
CLBK
IBRX
IBRX
Q4 25
28.6%
-169.0%
Q3 25
29.5%
-173.5%
Q2 25
25.8%
-269.8%
Q1 25
20.4%
-390.1%
Q4 24
-57.6%
-919.0%
Q3 24
13.5%
-1314.3%
Q2 24
9.0%
Q1 24
-2.6%
Net Margin
CLBK
CLBK
IBRX
IBRX
Q4 25
22.8%
-161.8%
Q3 25
22.1%
-209.8%
Q2 25
19.3%
-350.3%
Q1 25
15.1%
-784.9%
Q4 24
-45.7%
-783.4%
Q3 24
11.4%
-1404.0%
Q2 24
8.5%
Q1 24
-2.3%
EPS (diluted)
CLBK
CLBK
IBRX
IBRX
Q4 25
$0.15
$-0.06
Q3 25
$0.15
$-0.07
Q2 25
$0.12
$-0.10
Q1 25
$0.09
$-0.15
Q4 24
$-0.20
$-0.08
Q3 24
$0.06
$-0.14
Q2 24
$0.04
Q1 24
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLBK
CLBK
IBRX
IBRX
Cash + ST InvestmentsLiquidity on hand
$340.8M
$242.8M
Total DebtLower is stronger
$1.2B
Stockholders' EquityBook value
$1.2B
$-500.5M
Total Assets
$11.0B
$501.9M
Debt / EquityLower = less leverage
1.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLBK
CLBK
IBRX
IBRX
Q4 25
$340.8M
$242.8M
Q3 25
$253.4M
$257.8M
Q2 25
$248.2M
$153.7M
Q1 25
$256.1M
$61.6M
Q4 24
$289.2M
$149.8M
Q3 24
$283.5M
$130.4M
Q2 24
$391.1M
Q1 24
$373.5M
Total Debt
CLBK
CLBK
IBRX
IBRX
Q4 25
$1.2B
Q3 25
$1.3B
Q2 25
$1.3B
Q1 25
$1.1B
Q4 24
$1.1B
Q3 24
$1.4B
Q2 24
$1.7B
Q1 24
$1.5B
Stockholders' Equity
CLBK
CLBK
IBRX
IBRX
Q4 25
$1.2B
$-500.5M
Q3 25
$1.1B
$-524.3M
Q2 25
$1.1B
$-570.7M
Q1 25
$1.1B
$-591.4M
Q4 24
$1.1B
$-489.1M
Q3 24
$1.1B
$-745.1M
Q2 24
$1.0B
Q1 24
$1.0B
Total Assets
CLBK
CLBK
IBRX
IBRX
Q4 25
$11.0B
$501.9M
Q3 25
$10.9B
$519.0M
Q2 25
$10.7B
$402.1M
Q1 25
$10.6B
$303.8M
Q4 24
$10.5B
$382.9M
Q3 24
$10.7B
$364.6M
Q2 24
$10.8B
Q1 24
$10.6B
Debt / Equity
CLBK
CLBK
IBRX
IBRX
Q4 25
1.02×
Q3 25
1.11×
Q2 25
1.14×
Q1 25
1.01×
Q4 24
1.00×
Q3 24
1.32×
Q2 24
1.61×
Q1 24
1.47×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLBK
CLBK
IBRX
IBRX
Operating Cash FlowLast quarter
$68.4M
$-70.4M
Free Cash FlowOCF − Capex
$58.6M
$-71.3M
FCF MarginFCF / Revenue
85.1%
-186.2%
Capex IntensityCapex / Revenue
14.3%
2.4%
Cash ConversionOCF / Net Profit
4.36×
TTM Free Cash FlowTrailing 4 quarters
$95.1M
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLBK
CLBK
IBRX
IBRX
Q4 25
$68.4M
$-70.4M
Q3 25
$31.0M
$-68.9M
Q2 25
$14.6M
$-79.7M
Q1 25
$-1.6M
$-85.9M
Q4 24
$33.3M
$-85.1M
Q3 24
$-28.3M
$-98.8M
Q2 24
$18.6M
Q1 24
$14.1M
Free Cash Flow
CLBK
CLBK
IBRX
IBRX
Q4 25
$58.6M
$-71.3M
Q3 25
$28.1M
$-69.6M
Q2 25
$12.9M
$-80.8M
Q1 25
$-4.5M
$-87.0M
Q4 24
$25.9M
$-87.3M
Q3 24
$-31.1M
$-101.6M
Q2 24
$17.2M
Q1 24
$12.5M
FCF Margin
CLBK
CLBK
IBRX
IBRX
Q4 25
85.1%
-186.2%
Q3 25
41.8%
-217.2%
Q2 25
20.2%
-305.9%
Q1 25
-7.6%
-526.9%
Q4 24
55.7%
-1155.4%
Q3 24
-57.3%
-1663.2%
Q2 24
32.3%
Q1 24
25.1%
Capex Intensity
CLBK
CLBK
IBRX
IBRX
Q4 25
14.3%
2.4%
Q3 25
4.2%
2.3%
Q2 25
2.7%
4.1%
Q1 25
4.9%
6.8%
Q4 24
16.0%
28.0%
Q3 24
5.1%
45.7%
Q2 24
2.6%
Q1 24
3.4%
Cash Conversion
CLBK
CLBK
IBRX
IBRX
Q4 25
4.36×
Q3 25
2.08×
Q2 25
1.19×
Q1 25
-0.18×
Q4 24
Q3 24
-4.57×
Q2 24
4.09×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons